| Novartis drug Tasigna(R) meets primary endpoint in pivotal trial against ... - Reuters |
|
|
ReutersPatients with moderate renal impairment (CrCL = 20-39 mL/min) should receive a 50% decrease in the recommended starting dose, and future doses can be ...Tasigna - Novartis drug Tasigna® meets primary endpoint in pivotal trial ... read more |